WT-161 is a potent, selective, and bioavailable HDAC6 (histone deacetylase-6) inhibitor (IC₅₀ 0.40 nM). It is selective for HDAC6 over HDAC3 (IC₅₀ = 51.61 nM) and induces α-tubulin acetylation, an HDAC6-dependent process, with minimal effect on global lysine acetylation. WT161 inhibits growth of patient-derived multiple myeloma cell lines with IC₅₀ values ranging from 1.5 to 4.7 µM. WT161 enhances the cytotoxicity of bortezomib (Cat. No. 1846) and carfilzomib (Cat. No. 2385) against patient-derived multiple myeloma cells.
≥98% by HPLC